The phosphorylation of protein kinases leads to the activation of signal-transduction pathways, which have a critical role in a variety of biologic processes, including cell growth ...

Merck (MRK) announced that the U.S. FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for the treatment of patients with advanced or metastatic nonsquamous non-small cell ...

Merck & Co., Inc. (MRK) announced Tuesday that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ...

The FDA has granted Breakthrough Therapy designation to sacituzumab tirumotecan for patients with advanced or metastatic ...

Merck ( MRK, Financials) stated that sacituzumab tirumotecan (sac-TMT) was designated a Breakthrough Therapy by the FDA for advanced or metastatic nonsquamous non-small cell lung cancer with epidermal ...

Dysregulated cell signaling underlies various diseases, emphasizing the importance of understanding these pathways for ...

Janux Therapeutics' pipeline includes janx007, a tumor-activated T cell engager (TRACT) that targets prostate-specific ...

Regenerative medicine has the potential to reshape how we treat diseases, offering new hope for patients requiring cell, ...

Akeso, Inc. (9926. HK) ('Akeso' or the 'Company') is pleased to announce that two of its independently developed, globally ...

Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX – Get Free Report) have received an average rating of “Buy” from the six ...

China’s NRDL includes Akeso’s two bispecific antibody drugs, cadonilimab & ivonescimab: Hong Kong Friday, November 29, 2024, 10:00 Hrs [IST] Akeso, Inc., a leading biopharmace ...